Mesoblast Acquires Exclusive Global License for CAR Technology Platform
Mesoblast has acquired an exclusive worldwide license to a patented chimeric antigen receptor technology platform to enhance mesenchymal lineage stromal cell products for…
Mesoblast has acquired an exclusive worldwide license to a patented chimeric antigen receptor technology platform to enhance mesenchymal lineage stromal cell products for…